Collectively, our results demonstrate that miR-196a-3p and its downstream target NRP2 are involved in TGF-β-induced cell migration and invasion in invasive breast cancer cells, suggesting that restoring the expression of miR-196a-3p is a potential therapeutic approach for the treatment of breast cancer. This evidence concerns the gene NRP2 and breast carcinoma.